Gary W. Falk

Q: What Schools Are Affiliated With Gary W. Falk

Gary W. Falk is affiliated with the following schools: University of California, Berkeley, Princeton University, Stanford University, Case Western Reserve University, University of Rochester, University of Pennsylvania

Gary W. Falk's AcademicInfluence.com Rankings

Gary W. Falk

Physics

#6284

World Rank

#8211

Historical Rank

physics Degrees

Download Badge

Physics

Gary W. Falk's Degrees

Bachelors Physics University of California, Berkeley
PhD Physics Stanford University

Why Is Gary W. Falk Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gary W. Falk's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Eosinophilic esophagitis: updated consensus recommendations for children and adults. (2011) (1878)
ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus (2016) (1204)
Radiofrequency ablation in Barrett's esophagus with dysplasia. (2009) (1013)
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. (2018) (561)
A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. (2004) (556)
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. (2011) (446)
Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. (2006) (399)
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry (1999) (386)
The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. (1998) (384)
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. (2012) (383)
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial (2000) (367)
Thymic stromal lymphopoietin–elicited basophil responses promote eosinophilic esophagitis (2013) (336)
Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. (1999) (303)
Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. (1998) (269)
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. (2011) (245)
Surgical management of high-grade dysplasia in Barrett's esophagus. (1993) (229)
Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. (2013) (227)
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. (2011) (227)
Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. (1999) (225)
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. (2019) (222)
The gastric cardia: fact or fiction? (2000) (208)
In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). (2014) (190)
Superficial adenocarcinoma of the esophagus. (2001) (167)
An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. (2009) (160)
BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia (2015) (158)
Optical coherence tomography of the esophagus and proximal stomach in health and disease (2001) (142)
Practice patterns for surveillance of Barrett's esophagus in the united states. (2000) (137)
Caga-positive strains of Helicobacter pylori may protect against Barrett's esophagus (2000) (132)
Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad (1998) (131)
Familiality in Barrett's Esophagus, Adenocarcinoma of the Esophagus, and Adenocarcinoma of the Gastroesophageal Junction (2006) (130)
Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. (1997) (128)
The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on imaging in Barrett's Esophagus. (2012) (123)
Risk Factors for Dysplasia in Patients with Barrett's Esophagus (BE): Results from a Multicenter Consortium (2003) (119)
Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. (2000) (117)
Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. (2013) (115)
T-helper 2 cytokines, transforming growth factor β1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis. (2014) (110)
Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. (2010) (109)
Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. (2012) (104)
Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. (2020) (104)
Can extent of high grade dysplasia in Barrett’s oesophagus predict the presence of adenocarcinoma at oesophagectomy? (2003) (99)
Risk factors for esophageal cancer development. (2009) (99)
The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. (2009) (97)
Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. (2017) (94)
Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia (2006) (94)
Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. (2017) (93)
A coxib a day won't keep the doctor away (2004) (92)
Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. (2018) (90)
Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. (1994) (86)
Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. (2013) (83)
The natural history of eosinophilic oesophagitis in the transition from childhood to adulthood (2013) (82)
Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. (2015) (82)
The seroprevalence of -positive strains in the spectrum of gastroesophageal reflux disease (1998) (81)
Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. (2015) (81)
Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. (2017) (81)
Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course (2018) (80)
p53 expression in low grade dysplasia in Barrett’s esophagus: correlation with interobserver agreement and disease progression (2002) (77)
Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa (2002) (76)
Health‐Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review (2017) (72)
BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis. (2015) (71)
The Role of Allergy Evaluation in Adults With Eosinophilic Esophagitis (2010) (70)
Association of insulin and insulin-like growth factors with Barrett's oesophagus (2011) (69)
p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression (2002) (67)
Observer variation and reproducibility of endoscopic ultrasonography. (1995) (66)
Role of Helicobacter pylori cagA+ strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia (1999) (65)
Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens (2004) (62)
Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline (2022) (59)
The gastric cardia : Fact or fiction? (2000) (59)
Caga-positive strains of Helicobacter pylori may protect against Barrett’s esophagus (2000) (58)
The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes (2018) (58)
Gastric and Esophageal pH in Patients With Barrett's Esophagus Treated With Three Esomeprazole Dosages: A Randomized, Double-Blind, Crossover Trial (2006) (58)
Is FDG-PET indicated for superficial esophageal cancer? (2007) (57)
AGA Institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. (2006) (55)
Increasing Rates of Diagnosis, Substantial Co-occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis and Colitis Based on 10 Year Data Across a Multi-Center Consortium (2018) (55)
Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. (2013) (55)
213 A Randomized, Multicenter, Sham-Controlled Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's Esophagus (Be) Containing Dysplasia: Interim Results of the Aim Dysplasia Trial (2008) (55)
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. (2012) (55)
Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy. (2017) (53)
p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. (1994) (52)
Esophageal manometry: assessment of interpreter consistency. (2005) (50)
Demographic and phenotypic features of 70 families segregating Barrett’s oesophagus and oesophageal adenocarcinoma (2003) (47)
The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on peroral endoscopic myotomy. (2015) (47)
Location, location, location: does early cancer in Barrett's esophagus have a preference? (2013) (47)
Assessment of Upper Gastrointestinal Motility in the Cancer–Associated Dyspepsia Syndrome (1993) (46)
Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett’s Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium (2017) (46)
Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation (2002) (45)
Assessment of Familiality, Obesity, and Other Risk Factors for Early Age of Cancer Diagnosis in Adenocarcinomas of the Esophagus and Gastroesophageal Junction (2009) (45)
A Segregation Analysis of Barrett's Esophagus and Associated Adenocarcinomas (2010) (45)
Lower Annual Rate of Progression of Short‐Segment vs Long‐Segment Barrett's Esophagus to Esophageal Adenocarcinoma (2019) (44)
Barrett's Esophagus at a Tertiary Care Center: Association of Age on Incidence and Prevalence of Dysplasia and Adenocarcinoma (2006) (44)
Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. (2014) (44)
Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer. (2005) (43)
Acid Peptic Disorders (2019) (43)
Pancreatitis after sphincter of Oddi manometry. (1992) (43)
Clinical presentation and disease course of patients with esophagogastric junction outflow obstruction. (2017) (43)
Autophagy mediates epithelial cytoprotection in eosinophilic oesophagitis (2016) (41)
Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. (2016) (41)
Endoscopic surveillance of Barrett's esophagus (2000) (39)
Helicobacter pylori and acid peptic disorders of the esophagus: is it conceivable? (1997) (39)
Clinical Guidelines Update on the Diagnosis and Management of Barrett’s Esophagus (2018) (38)
Alignment of parent‐ and child‐reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites (2018) (38)
Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. (2015) (38)
A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus (2016) (38)
Esophageal cancer: The latest on chemoprevention and state of the art therapies. (2016) (37)
Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma. (2020) (37)
Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. (2016) (37)
Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus. (2015) (36)
Modeling inflammation and oxidative stress in gastrointestinal disease development using novel organotypic culture systems (2013) (35)
Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet? (2016) (34)
Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. (1999) (34)
Cryotherapy and Radiofrequency Ablation for Eradication of Barrett’s Esophagus with Dysplasia or Intramucosal Cancer (2018) (33)
Pathogenesis of gastroesophageal reflux and Barrett esophagus. (2001) (33)
Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids. (2020) (32)
Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study. (2004) (32)
A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus (2016) (31)
Esophageal epithelial cells acquire functional characteristics of activated myofibroblasts after undergoing an epithelial to mesenchymal transition. (2015) (31)
Reflux disease and Barrett's esophagus. (1999) (30)
Extent of Low-Grade Dysplasia in Barrett's Esophagus: Is It Useful for Risk Stratification? (2007) (30)
Autofluorescence endoscopy. (2009) (29)
Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders (2019) (29)
Management of Nondysplastic Barrett's Esophagus: Where Are We Now? (2009) (28)
Virtual Dysphagia Evaluation: Practical Guidelines for Dysphagia Management in the Context of the COVID-19 Pandemic (2020) (28)
Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. (2021) (28)
Progression of Barretl's esophagus to high grade dysplasia and cancer: Preliminary results of the BEST (Barrett's esophagus study) trial (2001) (27)
Gastroesophageal reflux disease and Barrett's esophagus. (2001) (27)
Adherence to the 2011 American Gastroenterological Association medical position statement for the diagnosis and management of Barrett's esophagus. (2015) (27)
Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multi-site cohort. (2020) (27)
Eosinophilic esophagitis: an increasingly recognized cause of dysphagia, food impaction, and refractory heartburn. (2008) (26)
Molecular, Endoscopic, Histologic and Circulating Biomarker-Based Diagnosis of Eosinophilic Gastritis: Multi-Site Study. (2019) (26)
Creating a multi-center rare disease consortium – the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) (2017) (26)
Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. (2020) (26)
Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress (2016) (25)
Eosinophilic Esophagitis-Associated Chemical and Mechanical Microenvironment Shapes Esophageal Fibroblast Behavior (2016) (25)
Endosonographic evaluation of the patient with achalasia: appearance of the esophagus using the echoendoscope. (1995) (25)
Variation in Age at Cancer Diagnosis in Familial versus Nonfamilial Barrett's Esophagus (2011) (25)
Eosinophilic Esophagitis: A Review. (2021) (25)
Fibrostenotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF-α. (2019) (24)
Brush cytology vs. endoscopic biopsy for the surveillance of Barrett's esophagus. (2010) (24)
Poor discriminatory function for endoscopic skills on a computer-based simulator. (2009) (24)
Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration. (2019) (23)
Persistent Basal Cell Hyperplasia is Associated with Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis. (2020) (23)
Barrett's esophagus: prevalence–incidence and etiology–origins (2011) (22)
Clinical outcomes in patients with a diagnosis of “indefinite for dysplasia” in Barrett’s esophagus: a multicenter cohort study (2015) (22)
Role of barium esophagography in evaluating dysphagia (2009) (22)
Pathogenesis of Gastroesophageal Reflux and Barrett Esophagus (2001) (22)
Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis (2020) (21)
Genomic regions associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study (2017) (21)
Associations of Serum Adiponectin and Leptin With Barrett's Esophagus. (2015) (20)
Corrigendum: ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus (2016) (20)
Advances in the treatment of esophageal carcinoma. (1997) (20)
Endoscopic ultrasound in the evaluation of Barrett's esophagus: a preliminary report. (1995) (19)
Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma. (2007) (18)
Effect of Pneumatic Dilation on Gastroesophageal Reflux in Achalasia (1997) (18)
Cytology in Barrett's esophagus. (2003) (18)
AGA Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease. (2006) (18)
Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium. (2019) (17)
International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. (2022) (17)
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS) (2021) (17)
Achalasia Patients Are at Nutritional Risk Regardless of Presenting Weight Category (2018) (16)
Is Conventional Endoscopic Identification of Non-Erosive Reflux Disease Adequate? (2008) (15)
Barrett's esophagus: endoscopic diagnosis (2011) (15)
Clinical presentation of eosinophilic esophagitis in adults. (2014) (15)
Barrett's esophagus. (2002) (15)
92 Durability of Epithelial Reversion After Radiofrequency Ablation: Follow-up of the AIM Dysplasia Trial (2010) (14)
Subsquamous intestinal metaplasia: implications for endoscopic management of Barrett's esophagus. (2012) (14)
Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus. (2015) (14)
Risk of malignant progression in Barrett's esophagus indefinite for dysplasia. (2017) (14)
Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. (2016) (14)
The possible role of Helicobacter pylori in GERD. (2001) (14)
Long-Term Treatment of Eosinophilic Esophagitis with Budesonide Oral Suspension. (2021) (14)
Anticardiolipin antibody-associated cerebral infarction in cirrhosis: clearance of anticardiolipin antibody after liver transplantation. (1994) (14)
Unresolved Issues in Barrett’s Esophagus in the New Millennium (2000) (14)
Long-Term Treatment of Eosinophilic Esophagitis with Budesonide Oral Suspension. (2021) (14)
Low Yield of Cross-Sectional Imaging in Patients with Esophagogastric Junction Outflow Obstruction. (2020) (14)
Radiofrequency ablation for Barrett's esophagus (2014) (13)
Antroduodenal manometry (2005) (13)
Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. (2015) (13)
Motility and GI Function Studies Billing and Coding Guidelines: A Position Paper of the American Motility Society (2003) (13)
GERD and H. pylori: is there a link? (2001) (13)
Barrett's oesophagus: frequency and prediction of dysplasia and cancer. (2015) (12)
Findings of Esophagography for 25 Patients After Peroral Endoscopic Myotomy for Achalasia. (2016) (12)
Interaction between patient and test administrator may influence the results of edrophonium provocative testing in patients with noncardiac chest pain. (1993) (11)
Primary biliary cirrhosis in a patient with multiple sclerosis. (1989) (11)
Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk. (2021) (11)
Modeling Epithelial Homeostasis and Reactive Epithelial Changes in Human and Murine Three-Dimensional Esophageal Organoids. (2020) (11)
Barrett's Esophagus—Is It Bad for Your Health? (2005) (11)
Results of Cryospray Ablation for Esophageal High Grade Dysplasia (HGD) and Intramucosal Cancer (IMCA) in High Risk Non-Surgical Patients (2008) (11)
Barrett's Esophagus. (2015) (11)
Barrett's esophagus and adenocarcinoma. The need for a consensus conference. (1996) (11)
Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. (2019) (11)
Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women. (2020) (10)
Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm (2016) (10)
TSLP-elicited basophil responses mediate the pathogenesis of eosinophilic esophagitis (2013) (10)
High‐resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma (2019) (10)
Obesity and gastroesophageal reflux disease: another piece of the puzzle. (2008) (10)
475c Low Risk of Developing Dysplasia and Esophageal Adenocarcinoma (EAC) in Patients With Non-Dysplastic Barrett's Esophagus (BE): Results From a Large, Multicenter, Cohort Study (2010) (10)
An Analysis of the GIQuIC Nationwide Quality Registry Reveals Unnecessary Surveillance Endoscopies in Patients With Normal and Irregular Z-Lines. (2020) (10)
Barrett's oesophagus length is established at the time of initial endoscopy and does not change over time: results from a large multicentre cohort (2015) (10)
Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study. (2021) (10)
ATG7 Gene Expression as a Novel Tissue Biomarker in Eosinophilic Esophagitis (2016) (10)
Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis. (2021) (10)
Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett's esophagus. (2020) (9)
Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. (2021) (9)
350 Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis in Adolescents and Adults: Results From a Phase 3, Randomized, Placebo-Controlled Trial (2019) (9)
Eosinophilic pancreatitis presenting as a pancreatic mass with obstructive jaundice. (2006) (9)
A Randomized, Double-Blind, Placebo-Controlled Trial of a Fluticasone Propionate Orally Disintegrating Tablet in Adult and Adolescent Patients with Eosinophilic Esophagitis: A Phase 1/2A Safety and Tolerability Study (2017) (9)
Comparison of esomeprazole, a novel PPI, vs omeprazole in GERD patients with erosive esophagitis (EE) (2000) (9)
Best Practices in Surveillance for Barrett's Esophagus. (2021) (8)
Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia (2015) (8)
Updated Guidelines for Diagnosing and Managing Barrett Esophagus. (2016) (8)
Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia (2015) (8)
The future of endoscopic treatment of early Barrett neoplasia: the endoscopist's view. (2008) (8)
Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms Following Dilation in Adults with Eosinophilic Esophagitis. (2021) (8)
Evidence for DNA damage checkpoint activation in barrett esophagus. (2010) (8)
Flow based single cell analysis of the immune landscape distinguishes Barrett’s esophagus from adjacent normal tissue (2019) (8)
Patient-derived organoids as a platform for modeling a patient’s response to chemoradiotherapy in esophageal cancer (2021) (8)
Relationship Between Barrett's Esophagus (BE) Length and the Risk of High Grade Dysplasia (HGD) and Esophageal Adenocarcinoma (EAC) in Patients With Non Dysplastic Barrett's Esophagus Results From a Large Multicenter Cohort (2011) (8)
Proton pump inhibitor-responsive oesophageal eosinophilia: too early to change clinical practice (2016) (8)
Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. (2022) (8)
Radiofrequency ablation of Barrett's esophagus: should everybody get it? (2009) (8)
Evaluating Eosinophilic Colitis as a Unique Disease using Colonic Molecular Profiles: A Multi-Site Study. (2022) (7)
High Patient Disease Burden in a Cross-sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases (2020) (7)
Esophageal strictures: Etiology and diagnosis (2001) (7)
Eosinophilic esophagitis: new insights into an emerging disease. (2006) (7)
Long-term outcomes for cryotherapy in Barrett's esophagus with high-grade dysplasia: just cracking the ice. (2017) (7)
Radiofrequency Ablation of Barrett’s Esophagus: Let’s Not Get Ahead of Ourselves (2010) (7)
Incidence of adenocarcinoma in Barrett's esophagus: Results of a multicenter prospective study. (2004) (6)
319 Recurrence of Intestinal Metaplasia After Eradication of Barrett's Esophagus With Radio Frequency Ablation - Results From a BETRNet Consortium (2012) (6)
Clinical Guideline : Diagnosis and Management of Barrett ' s Esophagus (2015) (6)
Current status of Helicobacter pylori in peptic ulcer disease. (1995) (6)
Chemoprevention and Barrett's Esophagus: Decisions, Decisions (2008) (6)
1136 In Vivo Endoscope-Based Confocal Laser Endomicroscopy (eCLE) Improves Detection of Unlocalized Barrett's Esophagus-Related Neoplasia Over High Resolution White Light Endoscopy: an International Multicenter Randomized Controlled Trial (2012) (6)
AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis (2020) (6)
The Volume-Outcome Effect Calls for Centralization of Care in Esophageal Adenocarcinoma: Results From a Large National Cancer Registry. (2021) (6)
Control of Acid and Duodenogastroesophageal Reflux (DGER) in Patients With Barrett’s Esophagus (2015) (6)
Columnar islands in Barrett's esophagus: Do they impact Prague C&M criteria and dysplasia grade? (2017) (6)
Laryngopharyngeal reflux: beauty is in the eye of the beholder. (2007) (5)
Sa1151 - Baseline Characteristics and Correlation Between Dysphagia and Disease Activity in Patients with Eosinophilic Esophagitis in a Randomized, Placebo-Controlled, Phase 2 Dupilumab Trial (2018) (5)
Refractory GERD: further insights into the cause of symptoms. (2008) (5)
Current Management of Low-Grade Dysplasia in Barrett Esophagus. (2017) (5)
Agreement Among Expert Gastrointestinal Pathologists for Low-Grade Dysplasia (LGD) in Barrett's Esophagus (BE) and Implications for Progression: Results From a Large, Multicenter Cohort Study (2011) (5)
Barrett's Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. (2014) (5)
962 Decreasing Rates of Esophageal Adenocarcinoma (EAC) in Patients With Persistent Non Dysplastic Barrett's Esophagus (NDBE): Results From a Large Multicenter Cohort (2012) (5)
Modeling Esophagitis Using Human Three-Dimensional Organotypic Culture System. (2017) (5)
Turning an idea into a grant. (2006) (5)
Reliability and Responsiveness of Endoscopic Disease Activity Assessment in Eosinophilic Esophagitis. (2022) (5)
M1104 Predicting High-Grade Dysplasia (HGD) and Esophageal Adenocarcinoma (EAC) in Patients With Non-Dysplastic Barrett's Esophagus (BE): Results From a Large, Multicenter Cohort Study (2010) (5)
Acute colonic pseudo-obstruction associated with interleukin-2 therapy. (1991) (5)
Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field? (2010) (5)
Development of quality indicators for the diagnosis and management of achalasia (2021) (5)
Management of Low-Grade Dysplasia in Barrett's Esophagus: Incremental Progress Continues. (2017) (5)
Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development (2019) (5)
Barrett's esophagus surveillance: When, how often, does it work? (2011) (5)
Regurgitation in a patient with an esophageal diverticulum. (1994) (5)
357 – Prospective Evaluation of a Novel, Endoscopic Activity Assessment System for Eosinophilic Gastritis (2019) (5)
Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas (2016) (4)
Correlation of the Eosinophilic Histopathological Scoring System with Esophageal Gene Expression in Patients with Eosinophilic Esophagitis (2018) (4)
Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort (2022) (4)
Mast cell‐pain connection in eosinophilic esophagitis (2022) (4)
The Volume-Outcome Effect Calls for Centralization of Care in Esophageal Adenocarcinoma: Results From a Large National Cancer Registry. (2020) (4)
Seattle biopsy protocol with jumbo biopsy forceps still misses unsuspected cancers in barrett's esophagus with high-grade dysplasia (1997) (4)
Barrett's esophagus: surveillance and reversal (2011) (4)
598 Eosinophil Derived TGF-ß1 Activates Human Esophageal Mesenchymal Cells and Alters Esophageal Motility - Implications for Dysphagia in Eosinophilic Esophagitis (EoE) (2012) (4)
Probe-based confocal endomicroscopy in Barrett's esophagus: the real deal or another tease? (2011) (4)
Cag A positivity may be protective against more severe grades of esophagitis (1998) (4)
Development and Validation of Web-Based Tool to Predict Lamina Propria Fibrosis in Eosinophilic Esophagitis (2021) (4)
T1879 Low-Grade Dysplasia (LGD) Is a Poor Marker for Cancer Progression in Patients with Barrett's Esophagus (BE): Preliminary Results from a Large, Multi-Center, Cohort Study (2009) (4)
CagA+ H. pylori colonization may prevent Barrett's esophagus (1998) (3)
Rio de Janeiro Global Consensus on Landmarks, Definitions and Classifications in Barrett's Esophagus: World Endoscopy Organization Delphi Study. (2022) (3)
Is the age of diagnosis of esophageal adenocarcinoma getting younger? Analysis at a tertiary care center. (2020) (3)
Endoscopic submucosal dissection for Barrett-associated neoplasia: is it ready for the endoscopist’s toolbox? (2015) (3)
Why is esophageal adenocarcinoma increasing in incidence? (1998) (3)
535 EFFICACY OF ONE-FOOD VERSUS SIX-FOOD ELIMINATION DIET FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS IN ADULTS: RESULTS FROM THE MULTICENTER RANDOMIZED CONTROLLED SOFEED TRIAL (2021) (3)
Current challenges in Barrett's esophagus. (2001) (3)
Type II achalasia is associated with a comparably favorable outcome following per oral endoscopic myotomy. (2020) (3)
An Analysis of the GIQuIC Nationwide Quality Registry Reveals Unnecessary Surveillance Endoscopies in Patients With Normal and Irregular Z-Lines. (2020) (3)
Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference. (2022) (3)
Evaluating the Association of Helicobacter pylori to GERD. (2008) (3)
Guideline to Practice: Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline (2022) (3)
60 Increased Detection of Barrett's Esophagus-Associated Neoplasia Using Wide Area Transepithelial Sampling in Conjunction With 4-Quadrant Forceps Biopsies: Final Results From a Multi-Center, Prospective, Randomized Trial (2016) (3)
Is the Extent of Low-Grade Dysplasia (LGD) in Barrett's Esophagus (BE) a Risk Factor for the Development of Esophageal Adenocarcinoma (EAC): Results From a Large, Multicenter Cohort Study (2011) (3)
A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. (2022) (3)
Overestimation of the diagnosis of eosinophilic colitis with reliance on billing codes. (2019) (3)
Novel Therapeutic Approaches to Eosinophilic Esophagitis. (2020) (3)
710 Safety and Outcomes of Radiofrequency Ablation for Barrett's Esophagus in Older Subjects: Results From a BETRNet Consortium (2012) (2)
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. (2023) (2)
Reflux disease and Barrett's esophagus. (1998) (2)
932 HISTOLOGIC AND SYMPTOMATIC IMPROVEMENT ACROSS MULTIPLE FORMS OF EOSINOPHILIC GASTROINTESTINAL DISEASES IN ENIGMA, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTOLIMAB (AK002) (2020) (2)
Mo1917 The Prague Classification Underestimates the True Maximal Extent and Dysplasia Grade of Barrett's Esophagus (2013) (2)
887 Integrated Pathways of Fibrogenesis in Eosinophilic Esophagitis: Active Secretion of Th2 Cytokines and TGF-β1, and Binding of Activated Eosinophils Promote Collagen I and Fibronectin Production By Human Esophageal Mesenchymal Cells (2009) (2)
Correction: Flow based single cell analysis of the immune landscape distinguishes Barrett’s esophagus from adjacent normal tissue (2019) (2)
665 Persistent Epithelial Changes in Inactive Eosinophilic Esophagitis: Is Inactive Really Inactive? (2016) (2)
Fluorescence in situ hybridization (FISH) of endoscopic brush cytology from barrett's esophagus detects genetic changes in high-grade dysplasia and adenocarcinoma not seen in patients without dysplasia (2003) (2)
H pylori 1997: testing and treatment options. (1997) (2)
Cutting to the chase: circumferential endoscopic mucosal resection for Barrett's neoplasia (2010) (2)
Normal Aging and the Esophagus (2013) (2)
140 – Diseases of the Esophagus (2012) (2)
1039 How Durable Is the Reversion to Neosquamous Epithelium in Subjects Undergoing Radiofrequency Ablation for Dysplastic Barrett's Esophagus? Two Year Follow-Up of the AIM-Dysplasia Randomized Sham-Controlled Trial (2009) (2)
EFFECT OF ESOMEPRAZOLE ON INTRAESOPHAGEAL pH IN PATIENTS WITH BARRETTʼS ESOPHAGUS: 46 (2004) (2)
Can FLIP guide therapy in idiopathic esophagogastric junction outflow obstruction? (2021) (2)
The Prevalence of GERD in Patients with Esophageal Adenocarcinoma (EAC) and Esophagogastric Junctional Adenocarcinoma (EGJAC) (2005) (2)
Sa1113 - Correlation Between Esophageal Distensibility and Objective Measures of Disease in Patients with Active Eosinophilic Esophagitis: A Post HOC Analysis of a Randomized, Placebo-Controlled, Phase 2 Dupilumab Trial (2018) (2)
Age of diagnosis in familial Barrett’s associated neoplasia (2021) (2)
S1056 The Prevalence of Dysplasia is Increasing in Patients With Newly Diagnosed Barrett's Esophagus (BE): Secular Trends From a Large, Multicenter, Cohort Study (2010) (2)
Lack of proton pump inhibitor trial prior to commencing therapy for eosinophilic esophagitis is common in the community. (2018) (2)
How exactly do i diagnose intestinal metaplasia in Barrett's esophagus? (2007) (2)
A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. (2022) (2)
Update on the use of radiofrequency ablation for treatment of barrett esophagus. (2013) (2)
Chapter 12 – Eosinophil-Mediated Tissue Remodeling and Fibrosis (2013) (1)
Identification of Myeloid Derived Suppressor Cells in the Barrett’s Metaplasia to Esophageal Adenocarcinoma Sequence (2017) (1)
Abstract PR-03: Aspirin mediated downregulation of Warburg kinase AKT1 in patients with Barrett's esophagus: Implications in neoplastic transformation (2012) (1)
Optical coherence tomography (OCT) characterization of Barrett's esophagus (BE) (2000) (1)
Mo1192 Lack of PPI Trial Prior to Commencing Therapy for Eosinophilic Esophagitis Is Common (2016) (1)
Cancer Risk in Barrett’S Esophagus patients (1992) (1)
539 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8 (2021) (1)
Natural History of Children with Eosinophilic Esophagitis (EoE) Transitioning to Adulthood: ACG/AstraZeneca Fellow Award: 63 (2011) (1)
Quality Indicators for the Diagnosis and Management of Eosinophilic Esophagitis. (2023) (1)
High Prevalence of Metabolic Syndrome in Patients with Barrett's Esophagus: A Multi-Center, Registry Study (2009) (1)
An Unusual Cause of Abdominal Pain. Appendiceal Intussusception Owing to Cecal Adenocarcinoma. (2015) (1)
Modeling inflammation and oxidative stress in gastrointestinal disease development using novel organotypic culture systems (2013) (1)
Examining the role of type 2 inflammation in eosinophilic esophagitis (2022) (1)
S445 Study of Compliance, Practice Patterns, and Barriers Regarding Established National Screening Programs for Barrett’s Esophagus Among Gastroenterology (GI) and Primary Care Providers (PCP): SCREEN-BE (2021) (1)
Tu1511 Lack of Discriminatory Function for Endoscopy Skills on a Computer-Based Simulator (2011) (1)
Night vision goggles for surveillance of Barrett's esophagus: a paradigm shift is coming! (2007) (1)
Seropositivity to CagA, HspA, and IgA identifies Helicobacter pylori strains that induce premalignant changes in the gastric cardia but not in the esophagus (1998) (1)
Su1461 The Impact of Wide-Area Endoluminal Resection on Endoscopic Therapy for Barrett's Dysplasia and Early Carcinoma (2013) (1)
Mo1187 DILATION REDUCES POSITIVE CORRELATION BETWEEN SYMPTOMS AND HISTOLOGIC FINDINGS IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS (2020) (1)
15 Insulin Resistance and Central Adiposity as a Risk Factors for Barrett's Esophagus (2010) (1)
Patient Knowledge, Risk Perception, and Barriers to Barrett's Esophagus Screening (2022) (1)
Development and Validation of a Prediction Model Associated with Neoplastic Progression of Barrettʼs Esophagus (BE): Data from a Multi-Center Prospective Cohort: 426 (2016) (1)
Gastroesophageal reflux disease. (2014) (1)
58 Recurrence Rates After Multi-Modality Endoscopic Eradication Therapy for Dysplastic Barrett's Esophagus (BE) and Early Esophageal Cancer: Results From an International, Multi-Center Consortium (2016) (1)
127 THE VOLUME-OUTCOME EFFECT CALLS FOR CENTRALIZATION OF CARE IN ESOPHAGEAL ADENOCARCINOMA (EAC): RESULTS FROM A LARGE NATIONAL CANCER REGISTRY (2020) (1)
Sa1038 DEVELOPMENT OF QUALITY INDICATORS FOR THE DIAGNOSIS AND MANAGEMENT OF ACHALASIA (2020) (1)
Management of Early-stage Esophageal Neoplasia (MESEN) Consensus (2013) (1)
Update on Ablation for Barrett’s Esophagus (2013) (1)
Mo1183 PREDICTORS OF RESPONSE TO CORTICOSTEROID THERAPY IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION (2020) (1)
W1901c Adults with Eosinophilic Esophagitis: What Is the Utility of Routine Allergy Evaluation? (2008) (1)
Sa1148 – The Majority of Patients with Confirmed Lgd in Barrett's Esophagus Progress Within the First Year of Diagnosis: Results from a Large Multicenter Be Consortium (2019) (1)
1037 Brush Cytology Versus Endoscopic Biopsy for Surveillance of Barrett's Esophagus (2009) (1)
Barrett's Esophagus: Diagnosis and Surveillance (2013) (1)
Inflammation of the gastric cardia [4] (multiple letters) (1999) (1)
S0345 Safety and Efficacy of Long-Term Treatment of EoE With Fluticasone Propionate Orally Disintegrating Tablet (APT-1011): Results From 40 Weeks Treatment in a Phase 2b Randomized Double-Blind Placebo-Controlled Trial (2020) (1)
CLINICAL—ALIMENTARY TRACT Risk Factors for Progression of Low-Grade Dysplasia in Patients With Barrett's Esophagus (2011) (1)
Endoscopic Features of Eosinophilic Esophagitis (2012) (1)
Low-grade dysplasia in Barrett's esophagus: More than meets the eye? (2021) (1)
Gastroesophageal reflux disease. (1999) (1)
Association of sporadic and familial Barrett's esophagus with breast cancer. (2018) (1)
Autofluorescence Endoscopy Is Inferior to White Light Endoscopy for Detection of Dysplasia/Cancer in Barrett's Esophagus Surveillance (2008) (1)
386 Mutational Analysis by Next-Generation Sequencing of Pre-Neoplastic Intestinal Metaplasia and Neoplastic Lesions in Barrett's Esophagus From Endoscopic Samples (2013) (1)
CLINICAL—ALIMENTARY TRACT A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus (2012) (1)
Optical coherence tomography (OCT) characterization of Barrett’s esophagus (BE) (2000) (1)
Omeprazole: a new drug for the treatment of acid-peptic diseases. (1991) (1)
IMPACT OF RACE AND GENDER ON OUTPATIENT ENDOSCOPY PROCEDURES DURING COVID: RESULTS FROM A LARGE POPULATION-BASED SURVEY (2022) (1)
Surveillance of Barrett's Esophagus (2007) (1)
Antireflux therapy in asthma: is there any role? (2009) (1)
710 Proton Pump Inhibitor Use but Not Statin Use Is Associated With Decreased Risk for High-grade Dysplasia and Esophageal Adenocarcinoma in Patients With Barrett's Esophagus: Results From a Large, Multicenter Cohort Study (2014) (1)
Sa1197 RATE AND CORRELATES OF PREVALENT, INTERVAL, AND INCIDENT ESOPHAGEAL CANCER (EC) AFTER DIAGNOSIS OF BARRETT'S ESOPHAGUS (BE): A POPULATION-BASED COHORT STUDY (2020) (1)
Sa1891 Increased Detection of Barrett's Esophagus (BE)-Associated Neoplasia Using Wide-Area Trans-Epithelial Sampling in Conjunction With 4-Quadrant Biopsies: Interim Results From a Multi-Center, Prospective, Randomized Trial (2015) (1)
[American Gastroenterological Association Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease]. (2006) (1)
Barrett's esophagus. (1994) (1)
230 STUDY OF COMPLIANCE, PRACTICE PATTERNS, AND BARRIERS REGARDING ESTABLISHED NATIONAL SCREENING PROGRAMS FOR BARRETT'S ESOPHAGUS AMONG PRIMARY CARE PROVIDERS (PCPS): SCREEN-BE (2021) (1)
Eosinophilic esophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross sectional study by the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) (2018) (1)
Mo1273 LOCATION AND PATTERN OF RECURRENCES IN PATIENTS WITH BARRETT’S ESOPHAGUS AFTER ENDOSCOPIC THERAPY: A SYSTEMATIC REVIEW AND CRITICAL ANALYSIS OF THE PUBLISHED LITERATURE (2020) (1)
772 PATIENTS COMMONLY UNDERGO BIOPSY OF A NORMAL OR IRREGULAR Z-LINE AND ARE RECOMMENDED ENDOSCOPIC SURVEILLANCE DESPITE THE ABSENCE OF BARRETT’S ESOPHAGUS: A POPULATION-BASED ANALYSIS USING THE GIQUIC NATIONAL QUALITY BENCHMARKING REGISTRY (2020) (0)
Sa1371 Modeling Esophageal Inflammation Using 3D Organotypic Culture System (2016) (0)
Real-World Evidence of Safety and Effectiveness of Barrett's Endoscopic Therapy. (2023) (0)
Sa1255 Low Risk of Neoplastic Progression of Barrett's Esophagus in Women: Results From a Large Multi-Center Consortium (2016) (0)
Generation and characterization of patient-derived esophageal cancer organoids (2020) (0)
Sa1859 Randomized Double Blind Placebo Controlled Phase II Trial of Barrett's Esophagus Chemoprevention With Metformin (2014) (0)
Proton pump inhibitor (PPI) treatment may not alter malignant progression in cases of Barrett’s metaplasia (BM) showing p53 protein accumulation (2000) (0)
Mo1203 OUTCOMES OF PATIENTS WHO FAIL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S ESOPHAGUS (2019) (0)
S410 Algorithm Training and Independent Test Set Performance for a Molecular Non-Endoscopic Test for Detection of Esophageal Adenocarcinoma and Barrett’s Esophagus in Multicenter Cohorts (2022) (0)
Sa1246 YOUNGER PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA (EAC) PRESENT WITH MORE ADVANCED DISEASE BUT EXHIBIT IMPROVED SURVIVAL: AN OUTCOMES STUDY USING THE NATIONAL CANCER DATABASE (2020) (0)
865 EOSINOPHILIC ESOPHAGITIS MAY FOSTER ESOPHAGEAL BASAL CELL HYPERPLASIA VIA NOTCH-INDEPENDENT EPITHELIAL RENEWAL (2020) (0)
204 Epithelial Lysyl Oxidase Is an Early Mediator of Fibrotic Remodeling in Eosinophilic Esophagitis (2015) (0)
Alginate Therapy Is Effective in the Treatment of Non-erosive Reflux Disease: A Systematic Review and Meta-analysis: 1681 (2015) (0)
W1896 Prospective Randomized Multicenter Study of FISH in Patients with Barrett's Esophagus (BE) (2009) (0)
W1051 Adherence to Surveillance Interval Guidelines in Barrett's Esophagus (BE): Analysis From a Large Multicenter Cohort Study (2010) (0)
Prognostic Risk Score From a Multicenter Cohort of Patients With T1b Esophageal Adenocarcinoma: 2017 Presidential Poster Award: 370 (2017) (0)
Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States (2023) (0)
165 – Development of the Eosinophilic Gastritis Molecular Diagnostic Panel (2019) (0)
Adenocarcinoma in Barrett’s Esophagus: Signs, Symptoms and Endoscopic Appearance (2001) (0)
Abstract 2593: Inhibition of COX1/2-driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development (2020) (0)
Tu1102 Are Clinical Outcomes in Indefinite for Dysplasia (IND) Any Different From Low Grade Dysplasia (LGD) in Patients With Barrett's Esophagus (BE)? Results From a Large Multicenter Cohort Study (2012) (0)
Su1153 An Assessment of Quality of Life in Adults Diagnosed With Eosinophilic Esophagitis in Childhood (2012) (0)
In reply: Barium esophagography (February 2009) (2009) (0)
A connection found between mast cells and pain in eosinophilic esophagitis (2022) (0)
AJG-21-1701 272..279 (0)
Su1990 Co-Culture With TH1 Polarized Pbmcs Enhances Growth of Human Intestinal Enteroids (2014) (0)
Trends in noncardiac chest pain. (1992) (0)
103 PATIENTS COMMONLY UNDERGO BIOPSY OF A NORMAL OR IRREGULAR Z-LINE AND ARE RECOMMENDED ENDOSCOPIC SURVEILLANCE DESPITE THE ABSENCE OF BARRETT’S ESOPHAGUS: A POPULATION-BASED ANALYSIS USING THE GIQUIC NATIONAL QUALITY BENCHMARKING REGISTRY (2020) (0)
Mo1894 Barrett's Esophagus Length Is Determined At the Time of Initial Development and Does Not Change Over Time: Results From a Large Multicenter Cohort (2013) (0)
Mo1853 Genetic Linkage Predisposing to Familial Barrett's Esophagus (FBE) (2013) (0)
Transition of Care from Pediatric to Adult Care in Eosinophilic Esophagitis: Insights From a Patient Perspective Survey (2021) (0)
Mo1165: ANTIBIOTIC EXPOSURE IS ASSOCIATED WITH INCREASED RISK OF ESOPHAGEAL ADENOCARCINOMA (2022) (0)
Increased Recognition of HGD/EAC at Index Endoscopy Over the Past 2 Decades: Data from a Multi-Center U.S. Consortium (2017) (0)
Su1473 Comparative Risk for Recurrence of Dysplasia and Carcinoma Following Endoluminal Eradication Therapy of High Grade Dysplasia vs Intramucosal Carcinoma in Barrett's Esophagus (2013) (0)
Presentation of the Julius M. Friedenwald Medal to Anil K. Rustgi. (2017) (0)
Truncated Caveolin-3 Mutation In Familial Barrett’s Esophagus (2022) (0)
Su1186: QUALITY INDICATORS FOR THE DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A DELPHI PROCESS (2022) (0)
Su1114 Autophagy-Related Gene 7 (ATG7) May Serve As a Biomarker of EoE Disease Status (2015) (0)
16 A Segregation Analysis of Barrett's Esophagus and Associated Adenocarcinomas (2010) (0)
Sa1462 Correlation Between Endoscopist Radiofrequency Ablation Volume and Response Rate in the Treatment of Barrett's Esophagus (2013) (0)
T1924 Familiality, Obesity, and Other Risk Factors for Early Age of Cancer Diagnosis in Adenocarcinomas of the Esophagus and Gastro-Esophageal Junction (2009) (0)
CLINICAL — ALIMENTARY TRACT Ef ﬁ cacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis (0)
TREATMENT OUTCOMES FOR POEM, HELLER MYOTOMY AND PNEUMATIC DILATION: A RETROSPECTIVE ANALYSIS AT A TERTIARY CARE CENTER (2022) (0)
Fr172 LOW RATES OF GLUCOCORTICOID-RELATED ADVERSE EFFECTS WITH LONG-TERM TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011): RESULTS FROM 52 WEEKS OF EXPOSURE IN A PHASE 2B TRIAL. (2021) (0)
840 Combining GWAS With Linkage Analysis Identifies a SNP Associated With Barrett's Esophagus And Esophageal Adenocarcinoma (2016) (0)
Sa1117 - Treatment Patterns for Eosinophilic Gastritis, Enteritis and Colitis Vary Across Sites and Patient Age in a Multi-Center Consortium (2018) (0)
Fr173 OPTIMIZATION OF EOSINOPHILIC GASTRITIS/DUODENITIS DETECTION REQUIRES EVALUATION OF MULTIPLE HIGH-POWERED FIELDS IN EACH OF 8 GASTRIC AND 4 DUODENAL BIOPSIES: ANALYSIS FROM A RANDOMIZED TRIAL (2021) (0)
Decision Making in Ablation: Disease, Patients, and Institutional Factors (2009) (0)
429 Maturational Changes in Esophageal Fibroblasts: Implications Upon the Natural History and Treatment of Eosinophilic Esophagitis (2014) (0)
Sa1525 Long Term Outcomes of Patients With Barrett's and HGD or Early Cancer Treated With Endoluminal Therapies With Intention to Complete Eradication (2011) (0)
Selection of patients for cancer prevention and eradication (2015) (0)
P400 BUDESONIDE ORAL SUSPENSION TREATMENT IMPROVES DYSPHAGIA SYMPTOMS IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (2019) (0)
A Strategy for Molecular Imaging of Barrett's Esophagus (BE) (2008) (0)
Chest Pain, Non-Cardiac (2004) (0)
Neoplastic Progression in Patients with Short Segment Barrett's Esophagus: Long-Term Follow-up of Over a 1000 Patients in a Multi-Center Consortium (2017) (0)
Mo1133 – High Patient-Reported Disease Burden for Eosinophilic Gastrointestinal Disorders (2019) (0)
Fr180 PILOT FEASIBILITY STUDY OF ENCAPSULATED BALLOON CELL SAMPLING DEVICE COMPARED TO ENDOSCOPY WITH BIOPSIES FOR THE EVALUATION OF EOSINOPHILIC ESOPHAGITIS (2021) (0)
Hepatitis C Virus. (2015) (0)
301 A Novel Tissue Systems Pathology Test Predicts Progression in Barrett's Esophagus Patients (2016) (0)
Dissecting mechanisms underlying the pathogenesis of eosinophilic esophagitis (HYP6P.263) (2014) (0)
Faculty Opinions recommendation of Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. (2011) (0)
S431 Associations of Dietary Fiber and Fat Intake with Barrett’s Esophagus and Stages of Progression to Esophageal Adenocarcinoma (2022) (0)
Esophagogastric Junction Outflow Obstruction: A Heterogeneous Entity of Unclear Clinical Significance: 458 (2016) (0)
Expression of human defensin-5 in Barrett's esophagus (2000) (0)
120 Risk of Malignant Progression in Barrett's Esophagus Indefinite for Dysplasia (2015) (0)
Tu1968 SEVOFLURANE INFLUENCES ESOPHAGOGASTRIC JUNCTION DISTENSIBILITY IN THE ABSENCE OF ESOPHAGEAL INFLAMMATION (2019) (0)
Lysyl Oxidase is a Novel Fibrostenotic Indicator in Eosinophilic Esophagitis Induced VIA the TNFÎ‘-TGFÎ' Axis in the Epithelial-Fibroblast Crosstalk (2017) (0)
Sa1826 Predicting Barrett's Esophagus in Families of Patients With Barrett's Esophagus: A BETRNet Model Fitting Clinical Data to a Genetic Paradigm (2014) (0)
Can a simple questionnaire enhance endoscopic screening for Barrett's esophagus? (2001) (0)
Sa1524 Pattern and Management of Recurrence in Patients With Barrett's and HGD or Early Cancer Treated With Endoluminal Therapies With Intention to Complete Eradication (2011) (0)
Risk of adenocarcinoma in short and long-segment Barrett's esophagus: Is shorter better? (1998) (0)
Sa1882 Autophagic Regulation of Oxidative Stress Promotes Esophageal Epithelial Cell Survival in Response to Acid Injury: Implications for Barrett's Esophagus Initiation and Progression (2015) (0)
Mo1918 Adherence to the 2011 AGA Medical Position Statement for the Treatment of Barrett's Esophagus (2013) (0)
The query corner (1998) (0)
ANTRODUODENAL MANOMETRY. AUTHOR'S REPLY (1992) (0)
BACTERIAL GASTROENTERITIS WITH ROTON PUMP INHIBITORS (0)
S0435 Determination of the Eosinophilic Esophagitis Endoscopic Reference Score Associated With Histologic Response to Therapy: Analysis From a Phase 3 Placebo-Controlled Trial of Budesonide Oral Suspension (2020) (0)
Cutting endoscopically or surgically for superficial esophageal adenocarcinoma. (2007) (0)
Editorial: fluticasone propionate orally disintegrating tablets—interesting concept but is it going anywhere? Authors’ reply (2020) (0)
Eosinophilic esophagitis. (2014) (0)
Sa1123 - Histologic Characterization of a Multi-Center Retrospective Cohort of Patients with Eosinophilic Gastrointestinal Disorders (2018) (0)
Mo1157: STUDY OF COMPLIANCE, PRACTICE PATTERNS, AND BARRIERS REGARDING ESTABLISHED NATIONAL SCREENING PROGRAMS FOR BARRETT'S ESOPHAGUS AMONG PATIENTS: THE SCREEN-BE STUDY (2022) (0)
228 INTERIM RESULTS OF AN OPEN-LABEL EXTENSION STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC ENTERITIS (2020) (0)
Faculty Opinions recommendation of Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. (2007) (0)
540 FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011) IMPROVES HISTOLOGIC, ENDOSCOPIC AND SYMPTOMATIC RESPONSES IN EOSINOPHILIC ESOPHAGITIS PATIENTS WITH FIBRO-STENOTIC FEATURES: RESULTS FROM A PHASE 2B TRIAL (2021) (0)
Su1178 Matrix-Stiffness Enhances Esophageal Fibroblast Activation, Proliferation and Contractility in Pediatric and Adult Fibroblasts (2015) (0)
278 PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS (2020) (0)
539 Dysplasia Recurrence After Complete Eradication of Intestinal Metaplasia (CEIM) and Dysplasia (CED) in Barrett's Esophagus Treated With Endoscopic Therapy: Results From an International, Multi-Center Consortium (2017) (0)
AJG-21-0760 413..423 (0)
Unifocal versus multifocal high-grade dysplasia in Barrett's esophagus does not predict adenocarcinoma at esophagectomy (2001) (0)
S1421 Safety and Efficacy of Long-Term Treatment With Lirentelimab, A Monoclonal Antibody Against Siglec-8, in Patients With Eosinophilic Gastritis and/or Duodenitis (2021) (0)
Iconographies supplémentaires de l'article : Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study (2020) (0)
Erratum to: Radiofrequency Ablation of Barrett’s Esophagus: Let’s Not Get Ahead of Ourselves (2010) (0)
Sa1254 The Extent of Barrett's Esophagus Predicts Resistance to Successful Endoscopic Eradication Therapy for Barrett's Esophagus (BE) With Dysplasia or Early Cancer (EAC): Results From an International, Multi-Center Consortium (2016) (0)
Tu1234 – Cross-Sectional Imaging in Patients with Esophagogastric Junction Outflow Obstruction: Time to Stop? (2019) (0)
Sa1152 – Age of Diagnosis in Familial Esophageal Adenocarcinoma (2019) (0)
526 Autophagy Is an Epithelial Cytoprotective Mechanism in Esophageal Epithelial Cells in Response to Eosinophilic Esophagitis-Associated Inflammation (2015) (0)
Su1001 CLINICAL CHARACTERISTICS AND DISEASE FEATURES FROM A MULTICENTER LONGITUDINAL COHORT OF EOSINOPHILIC GASTROINTESTINAL DISORDERS MAY INFORM FUTURE STUDIES (2020) (0)
Award Number: W81XWH-11-1-0507 TITLE: Exploration into the Genetics of Food Allergy (2014) (0)
Sa1116 - Demographic Features of Eosinophilic Gastritis, Enteritis and Colitis Using 10 Years of Retrospective Data from a Multi-Center Consortium (2018) (0)
Good news for the treatment of narrow-caliber esophagus in eosinophilic esophagitis. (2020) (0)
1080 - Dysplasia Free Survival in Patients with Barrett's Esophagus after Successful Endoscopic Therapy: Results from a Large Multicenter Consortium (2018) (0)
Mo1185 Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders (EGID) (2016) (0)
Mo1013 INCREASING INCIDENCE OF ESOPHAGEAL ADENOCARCINOMA OCCURS IN OLDER ADULTS AND CONTRASTS WITH THE RISE OF COLORECTAL CANCER IN THE YOUNG: A UNITED STATES POPULATION-BASED STUDY (2020) (0)
621 PL02.05 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8 (2021) (0)
Mo1248 RECURRENCE OF GASTRO-ESOPHAGEAL JUNCTION INTESTINAL METAPLASIA AFTER ENDOSCOPIC ERADICATION OF BARRETT'S ESOPHAGUS IS NOT ASSOCIATED WITH INCREASED RATES OF DYSPLASIA RECURRENCE: RESULTS OF A MULTI-CENTER COHORT STUDY (2020) (0)
Proton pump inhibitor (PPI) treatment may not alter malignant progression in cases of Barrett's metaplasia (BM) showing p53 protein accumulation (2000) (0)
Telomerase — A potential biomarker of adenocarcinoma in Barrett's esophagus (2001) (0)
169 – Interleukin-13-Mediated Release of Mitochondrial Dna from Esophageal Epithelial Cells: A Novel Biomarker for Eosinophilic Esophagitis (2019) (0)
Persistent Basal Cell Hyperplasia in Patients with Inactive Eosinophilic Esophagitis: A New Tool for Understanding a Poorly Defined Population (2017) (0)
Interobserver Agreement and Accuracy in Prediction of Barrett's-Associated Neoplasia Among More-Experienced and Less-Experienced Endomicroscopists (2011) (0)
Clonal cell states link Barrett’s esophagus and esophageal adenocarcinoma (2023) (0)
S356 Long-Term (> 5 Year) Outcomes of Endoscopic Resection for T1 Esophageal Adenocarcinoma: A Multicenter Cohort Study (2021) (0)
Esophageal Distensibility in Proton Pump Inhibitor Responsive Esophageal Eosinophilia is Decreased Compared to Controls (2017) (0)
2017 David Sun Lecture: Screening and Surveillance of Barrett's Esophagus: Where Are We Now and What Does the Future Hold? (2019) (0)
Incidence of adenocarcinoma in Barrett's esophagus: Results of a multicenter prospective study (2004) (0)
Su1119 COMPLETE ERADICATION OF INTESTINAL METAPLASIA AND DYSPLASIA AFTER MULTI-MODALITY ENDOSCOPIC THERAPY FOR DYSPLASTIC BARRETT’S ESOPHAGUS (BE) WITH VISIBLE MUCOSAL LESIONS: RESULTS FROM A MULTI-CENTER CONSORTIUM (2018) (0)
Tu1315 ADHERENCE TO QUALITY INDICATORS IN THE ENDOSCOPIC DIAGNOSIS AND SURVEILLANCE OF BARRETT'S ESOPHAGUS (2020) (0)
Patient Factors Associated With Gastroesophageal Reflux Disease Diagnostic Evaluation Strategies: A Retrospective Cohort Study Using Real-World Evidence From a Large U.S. Medical Claims Database (2022) (0)
Antibiotic exposure is associated with a risk of esophageal adenocarcinoma. (2023) (0)
Sa1838 CDx2 Expression Reduces Disease Progression in the L2-IL-1Beta Mouse Model for Barrett's Esophagus (2014) (0)
Diagnosis and Surveillance of Barrett's Esophagus (2012) (0)
S3265 Online CME on Eosinophilic Gastrointestinal Diseases Improves Knowledge and Competence Among Gastroenterologists (2021) (0)
Su1173: EFFECT OF PRIOR ESOPHAGEAL DILATION ON HISTOLOGIC, SYMPTOM AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: POST HOC ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION (2022) (0)
Photodynamic Therapy in Barrettʼs Esophagus with High Grade Dysplasia and Intra-Mucosal Carcinoma: 66 (2006) (0)
Mo1171 ARTIFICIAL INTELLIGENCE (AI) BASED ANALYSIS OF INESTINALIZATION MARKERS SUPPORTS NON-GOBLET CELL PATHWAY FOR THE DEVLOPMENT OF HIGH GRADE DYSPLASIA (HGD) IN BARRETT'S ESOPHAGUS (2020) (0)
Sa1523 Influence of Barrett's Length on Characterization, Treatment and Long-Term Outcomes in Patients With HGD or Intramucosal Carcinoma Undergoing Endoscopic Therapy (2011) (0)
Four Approaches to Reinvigorate Learning for the 21st Century Gastroenterologist. (2016) (0)
Defining the Rates of Missed and Interval High-Grade Lesions in Patients With Barrettʼs Esophagus: Results From a Large Multicenter Study: 308 (2017) (0)
Fr174 TIME TO FIRST DYSPHAGIA SYMPTOM RESPONSE IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: POST HOC ANALYSIS FROM A PHASE 3 TRIAL OF BUDESONIDE ORAL SUSPENSION (2021) (0)
Age-Associated Decline in Esophageal Autophagy Flux Contributes to Fibrosis in Eosinophilic Esophagitis (2017) (0)
Treatment of Helicobacter pylori in nonulcer dyspepsia: should we or shouldn't we? (1999) (0)
Red Meat Intake is Associated With Increased Risk of Barrett's Esophagus (2011) (0)
Tu1016 OCCURRENCE OF ESOPHAGEAL ADENOCARCINOMA IN THE YOUNG IS UNCOMMON AND PRESENTS WITH MORE ADVANCED STAGE YET IMPROVED SURVIVAL: A POPULATION-BASED STUDY (2020) (0)
460 - Inflammatory Cytokines Diminish Notch Signaling to Drive Reactive Epithelial Changes in Eosinophilic Esophagitis (2018) (0)
Fr176 ENDOSCOPIC APPEARANCE DOES NOT PREDICT THE PRESENCE OF HISTOLOGIC EOSINOPHILIC GASTRITIS AMONG SYMPTOMATIC ADULTS, INDICATING THAT COLLECTION AND EVALUATION OF BIOPSIES SHOULD OCCUR REGARDLESS OF ENDOSCOPIC APPEARANCE: ANALYSIS FROM A RANDOMIZED TRIAL (2021) (0)
407 Autophagy May Facilitate Epithelial-Mesenchymal Transition in Eosinophilic Esophagitis and Genetically Engineered Mouse Models of Esophagitis (2013) (0)
Evidence for DNA Damage Checkpoint Activation in (2010) (0)
Foreword. Biologics of IBD. (2014) (0)
9 - Barrett's Esophagus International Consortium Study: Detection of Post-Endoscopy Neoplastic Progression in Patients Undergoing Surveillance (2018) (0)
Tu1159 Long Term Outcomes of Multiband Mucosectomy for Dysplastic Barrett's (2017) (0)
Sa1161 – Late Recurrence of Dysplastic Barrett's Esophagus and Esophageal Adenocarcinoma After Endoscopic Eradication Therapy (2019) (0)
818 – Cytokine Expression Illustrates Heterogeneity of Active Eosinophilic Esophagitis in a Large Multi-Site Cohort (2019) (0)
Identification of Genomic Regions Associated with Susceptibility to Barrett’s Esophagus and Esophageal Adenocarcinoma in African Americans: The Cross Betrnet Admixture Study (2017) (0)
W1700 Eosinophils and Their Products Activate Human Esophageal Mesenchymal Cells – Implications for Fibrogenesis in Eosinophilic Esophagitis (EoE) (2010) (0)
990: EFFECT OF RANDOMIZED WITHDRAWAL OF BUDESONIDE ORAL SUSPENSION ON EFFICACY IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: POST HOC ANALYSIS OF HISTOLOGIC, SYMPTOM AND ENDOSCOPIC OUTCOMES (2022) (0)
839 Should We Discontinue Surveillance in Patients With Irregular z line (<1 cm Barrett's Esophagus): Results from a Large, Multicenter, Cohort Study (2016) (0)
Mucosal Microbiota Associated With Eosinophilic Esophagitis and Eosinophilic Gastritis (2022) (0)
S353 Time to Clinically Meaningful Improvement in Dysphagia Frequency in Adults with Eosinophilic Esophagitis: A Post-Hoc Analysis From a Phase 2b Trial of APT-1011, a Fluticasone Propionate Oral Disintegrating Tablet (2021) (0)
Inflammatory Mediators in Gastroesophageal Reflux Disease 4 ( GERD ) : Impact on Esophageal Motility , Fibrosis and 5 Carcinogenesis 6 7 8 (2010) (0)
Esophageal Lichen Planus and Development of Dysplasia (2022) (0)
Mo1161 – The Endoscopic Burden of Eosinophilic Esophagitis Over a 10-Year Period (2019) (0)
Su1196: EFFECT OF TIME SINCE DIAGNOSIS ON EFFICACY OUTCOMES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: POOLED DATA FROM A PHASE 2 AND A PHASE 3 TRIAL OF BUDESONIDE ORAL SUSPENSION (2022) (0)
Sa1163 - Lamina Propria Fibrosis and Eosinophil Count do not Correlate with Esophageal Distensibility in Eosinophilic Esophagitis (2018) (0)
Mo1922 Adherence to the 2011 AGA Medical Position Statement for the Diagnosis, Screening, and Surveillance of Barrett's Esophagus (2013) (0)
Su1174: CORRELATIONS OF ENDOSCOPIC REFERENCE SCORE AND DISTENSIBILITY PLATEAU IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS (2022) (0)
Esophageal Epithelium and Lamina Propria are Unevenly Involved in Eosinophilic Esophagitis. (2023) (0)
H. Pylori (HP), not GERD, is the major cause of inflammation and intestisal metaplasia (IM) of the native gastric cardia (2001) (0)
Helicobacter pylori and GERD (2021) (0)
Tu1250 Exceptional Families With Barrett's Esophagus, Esophageal Adenocarcinoma, and Breast Cancer (2016) (0)
Mo1182 AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA ACCURATELY CAPTURES RESPONSE TO TREATMENT WITH APT-1011 IN A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS (2020) (0)
Su1754 – Overestimation of the Prevalence of Eosinophilic Colitis with Reliance on a Single Billing Code (2019) (0)
Preface: GI Clinics of North America (2008) (0)
Caveolin-3 Null Mutation in Family with Barrett’s Esophagus and Esophageal Adenocarcinoma (2021) (0)
Sa1657 - Increased Notch Signaling and Loss of Goblet Cell Differentiation with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma: A Betrnet Study (2018) (0)
Sa1257 A Tissue Systems Pathology Test Detects a Field Effect Associated With High Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus Patients (2016) (0)
反流性食管炎中埃索美拉唑比奥美拉唑更能促进病变愈合和症状缓解 (2002) (0)
Contributors (2012) (0)
463 - Rapamycin-Mediated Autophagy Activation Ameliorates Eoeassociated Alterations in Epithelial Tissue Architecture (2018) (0)
The Slender Esophagus: Unrecognized Esophageal Narrowing in Eosinophilic Esophagitis (2023) (0)
S0404 Improved Histopathologic Features in Patients With Eosinophilic Esophagitis: Results and Analyses From a Phase 3, Randomized, Placebo-Controlled Trial of Budesonide Oral Suspension (2020) (0)
Despite Histologic Remission in Eosinophilic Esophagitis, Esophageal Distensibility Does Not Have Short-Term Changes (2018) (0)
Bariatric Surgery Protects Against Barrett’s Esophagus and Esophageal Adenocarcinoma: A National Database Study (2021) (0)
444 Unmet Need for Additional Resources to Support Successful Transition of Care From Pediatric to Adult Providers for the Management of Eosinophilic Gastrointestinal Diseases (2019) (0)
Su1167: THE ASSOCIATION BETWEEN HISTOLOGIC ABNORMALITIES AND HEALTH RELATED QUALITY OF LIFE IN PEDIATRIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (2022) (0)
S389 Patient Factors Associated With Gastroesophageal Reflux Disease Diagnostic Evaluation Strategies: A Retrospective Cohort Study (2021) (0)
Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States (2023) (0)
1155 Impact of Complete Eradication of Intestinal Metaplasia (CEIM) Definition on Recurrence of Barrett's Esophagus After Successful Endoscopic Therapy: Results From an International, Multi-Center Consortium (2017) (0)
T1899 Insulin Resistance As a Risk Factor for Barrett's Esophagus (2009) (0)
Sa1864 Aspirin Downregulates Cell Survival and mTOR Effector pS6K in Barrett's Esophagus Patients: Data From a Randomized, Double-Blind, Phase II Chemoprevention Trial (2014) (0)
Su185 CAN ENDOFLIP GUIDE THERAPY IN IDIOPATHIC ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTION? (2021) (0)
871 Eosinophilic Esophagitis (EoE)-Associated Eosinophil Products and Cytokines Reduce Neurogenic Esophageal Smooth Muscle Contractility (2010) (0)
Su1119 – Is the Age of Diagnosis of Esophageal Adenocarcinoma Getting Younger? Analysis At a Tertiary Care Center (2019) (0)
Su1172 Induction of Autophagy in Barrett's Esophagus and in Response to Acid Injury (2012) (0)
Upper GI bleeding. (2014) (0)
Pilot Feasibility Study of Encapsulated Balloon in Assessing Response to Eosinophilic Esophagitis Therapy (2022) (0)
Efficacy And Safety Of Budesonide Oral Suspension In A Pediatric Population: Pooled Data From A Phase 2 And Phase 3 Trial In Patients With Eosinophilic Esophagitis (2021) (0)
Women with Barrett's esophagus (BE): Are they different from men? (2003) (0)
416 Eosinophilic Esophagitis Is Associated with Active and Uniform Secretion of Th-2 Cytokines and Reduced Esophageal Smooth Muscle Contractility (2008) (0)
Abstract CN06-03: Randomized double-blinded phase II trial of esomeprazole versus esomeprazole + two doses of aspirin in Barrett's esophagus patients (2011) (0)
Su1870 Serial Endoscopy in Eosinophilic Esophagitis: Treat & Titrate or Treat & Leave Alone? (2013) (0)
Fr191 EOSINOPHILIC GASTRITIS AND EOSINOPHILIC DUODENITIS EXHIBIT A SIMILAR CLINICAL PRESENTATION, UNDERSCORING THE NEED FOR COLLECTION OF MULTIPLE BIOPSIES FROM BOTH THE STOMACH AND DUODENUM TO EVALUATE FOR TISSUE EOSINOPHILIA: ANALYSIS FROM A RANDOMIZED TRIAL (2021) (0)
Sa1850 Should We Continue to Follow Patients With <1 CM Barrett's Esophagus (Irregular Z Line): Results From a Large, Multicenter, Cohort Study (2014) (0)
693: PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA WITH PRIOR GERD SYMPTOMS ARE SIMILAR TO THOSE WITHOUT GERD: A PROSPECTIVE CROSS-SECTIONAL STUDY (2022) (0)
Refractory eosinophilic esophagitis: what to do when the patient has not responded to proton pump inhibitors, steroids and diet (2022) (0)
536 COMPLICATIONS OF ENDOSCOPIC MUCOSAL RESECTION IN BARRETT’S ESOPHAGUS ARE DIRECTLY RELATED TO THE NUMBER OF RESECTED SPECIMENS: RESULTS FROM A LARGE MULTI-CENTER CONSORTIUM (2018) (0)
Fr171 LOSS OF HISTOLOGIC, SYMPTOM AND ENDOSCOPIC EFFICACY FOLLOWING TREATMENT WITHDRAWAL IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: A PHASE 3, RANDOMIZED WITHDRAWAL STUDY OF BUDESONIDE ORAL SUSPENSION (2021) (0)
Fr179 CHARACTERISTICS OF EOSINOPHILIC ESOPHAGITIS IN A DIVERSE COHORT OF PEDIATRIC AND ADULT PATIENTS: A MULTI-SITE STUDY (2021) (0)
Age of diagnosis in familial Barrett’s associated neoplasia (2021) (0)
Tu1079 Adherence to Surveillance Guidelines in Patients With Barrett's Esophagus (BE): Analysis From a Large Multicenter Cohort Study (2014) (0)
Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. (2021) (0)
Abstract 4253: Modeling the effects of inflammatory stress on human intestinal epithelial cells in 3D enteroid co-culture system (2016) (0)
898 Title: Insulin Like Growth Factor (IGF) Signaling Pathway in Barrett's Esophagus (BE) (2009) (0)
Genomic Testing of Endoscopic Biopsies Aid in the Identification of Barrett's Esophagus Patients Who Progress to Dysplasia (2017) (0)
1244 Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Enteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia: A New Diagnostic Entity? (2019) (0)
227 BUDESONIDE ORAL SUSPENSION (BOS) IMPROVES ENDOSCOPIC ACTIVITY IN ADOLESCENTS AND ADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS AND CORRELATION ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (2020) (0)
1152 Outcomes of Patients With T1B Esophageal Adenocarcinoma: A Multicenter Cohort Study (2017) (0)
A Delphi Method for Development of a Barrett's Esophagus Question Prompt List as a Communication Tool for Optimal Patient-physician Communication. (2023) (0)
ID: 3524123 STUDY OF COMPLIANCE, PRACTICE PATTERNS, AND BARRIERS REGARDING ESTABLISHED NATIONAL SCREENING PROGRAMS FOR BARRETT'S ESOPHAGUS AMONG GASTROENTEROLOGY PROVIDERS: SCREEN-BE (2021) (0)
Reply to Dr. Chandrasoma (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gary W. Falk?

Gary W. Falk is affiliated with the following schools:

University of California, Berkeley
Princeton University
Stanford University
Case Western Reserve University
University of Rochester
University of Pennsylvania